Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss
DOI: https://doi.org/10.2147/clep.s456170
2024-04-25
Clinical Epidemiology
Abstract:Aurélie Mailhac, 1 Lars Pedersen, 1 Anton Pottegård, 2 Jens Søndergaard, 3 Torben Mogensen, 4 Henrik Toft Sørensen, 1 Reimar W Thomsen 1 1 Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark; 2 Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark; 3 Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark; 4 Danish Pharmacovigilance Council, Danish Medicines Agency, Copenhagen, Denmark Correspondence: Reimar W Thomsen, Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark, Email Purpose: A surge in the use of semaglutide injection (Ozempic ® ) approved to treat type 2 diabetes (T2D) has led to a global supply shortage. We investigated contemporary user rates and clinical characteristics of semaglutide (Ozempic ® ) users in Denmark, and the extent of "off-label" prescribing for weight loss. Patients and Methods: Nationwide population-based cross-sectional study based on linked health registries January 2018 through December 2023. All adults who received a first prescription of semaglutide once weekly (Ozempic ® ) were included. We examined quarterly rates of new users and total user prevalences, using other glucagon-like peptide-1 receptor agonists and weight loss medications as comparison. We also investigated user characteristics including T2D, glucose control, comedications, and cardiorenal disease. Results: The new user rate of semaglutide (Ozempic ® ) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then accelerated, peaking at 10 per 1000 in the first quarter of 2023 after which it declined sharply. User prevalence increased to 91,626 users in Denmark in 2023. The proportion of semaglutide (Ozempic ® ) new users who had a record of T2D declined from 99% in 2018 to only 67% in 2022, increasing again to 87% in 2023. Among people with T2D who initiated semaglutide (Ozempic ® ) in 2023, 52% received antidiabetic polytherapy before initiation, 39% monotherapy, and 8% no antidiabetic therapy. Most T2D initiators had suboptimal glucose control, with 83% having an HbA1c ≥ 48 mmol/mol and 68% ≥ 53 mmol/mol despite use of antidiabetic medication, and 29% had established atherosclerotic cardiovascular disease or kidney disease. Conclusion: The use of semaglutide (Ozempic ® ) in Denmark has increased dramatically. Although not approved for weight loss without T2D, one-third of new users in 2022 did not have T2D. Conversely, most initiators with T2D had a clear medical indication for treatment intensification, and "off-label" use can only explain a minor part of the supply shortage. Keywords: drug utilization, epidemiology, anti-obesity drugs, glucose-lowering drugs, obesity, type 2 diabetes Worldwide the prevalence of obesity and type 2 diabetes (T2D) is high and rapidly increasing. 1 Substantial progress has been made over the past decade in the pharmacological management of T2D, 2,3 and recently also obesity. 4,5 In developed countries, new classes of organ-protective glucose-lowering drugs, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT-2i), have now become central to the treatment of T2D. 2,3 Despite being developed to treat hyperglycemia in T2D, GLP-1RAs at high doses have clinically significant effects on body weight in people with obesity. 4 Consequently, several GLP-1RA injections are presently approved to treat T2D at a single recommended maintenance dose, and simultaneously licensed for treating obesity, but at a higher recommended maintenance dose. For instance, semaglutide injection at 1.0 mg once weekly (marketed as Ozempic ® ) and liraglutide injection 1.2 or 1.8 mg once daily (sold as Victoza ® ) are approved for T2D treatment, whereas semaglutide injection 2.4 mg once weekly (sold as Wegovy ® ) and liraglutide injection 3.0 mg once daily (sold as Saxenda ® ) are approved for treating obesity. 4,5 Moreover, there is now randomized trial evidence for effectiveness of GLP-1RAs in secondary prevention of cardiovascular disease, 6 not only in patients with T2D, 7–9 but also in overweight or obese patients without diabetes. 10 A surge in the use of semaglutide injection (Ozempic ® ) has occurred in many countries since 2022, creating a global -Abstract Truncated-
public, environmental & occupational health